[177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer

Ute Hennrich; Matthias Eder

doi:10.3390/ph15101292

[¹⁷⁷Lu]Lu-PSMA-617 (Pluvicto^TM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer

Pharmaceuticals (Basel). 2022 Oct 20;15(10):1292. doi: 10.3390/ph15101292.

Authors

Ute Hennrich¹, Matthias Eder^{2

3}

Affiliations

¹ German Cancer Research Center (DKFZ), Service Unit Radiopharmaceuticals and Preclinical Studies, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
² Division of Radiopharmaceutical Development, German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany and German Cancer Research Center, 69120 Heidelberg, Germany.
³ Department of Nuclear Medicine, University Medical Center Freiburg, University of Freiburg, Faculty of Medicine, 79106 Freiburg, Germany.

Abstract

In March 2022, [¹⁷⁷Lu]Lu-PSMA-617 (Pluvicto^TM) was approved by the FDA for the treatment of prostate cancer patients. Until now, the approval has been limited to patients with PSMA-positive metastatic castration-resistant prostate cancer who have previously received other therapy options (such as inhibition of the androgen receptor pathway and taxane-based chemotherapy). [¹⁷⁷Lu]Lu-PSMA-617, which combines a PSMA-specific peptidomimetic with a therapeutical radionuclide, is used in a radioligand therapy that selectively delivers ionizing radiation to tumor cells, causing their death, while sparing the surrounding healthy tissue. In numerous clinical trials, the efficacy of [¹⁷⁷Lu]Lu-PSMA-617 was demonstrated.

Keywords: PSMA; PluvictoTM; [177Lu]Lu-PSMA-617; prostate cancer; radioligand therapy (RLT); theranostics.

Publication types

Review

Grants and funding

This research received no external funding.